Ramatroban (BioDeep_00000600943)

   


代谢物信息卡片


3R-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid

化学式: C21H21FN2O4S (416.12059980000004)
中文名称: 雷马曲班
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
InChI: InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1

描述信息

COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

3 个代谢物同义名

Ramatroban; 3R-[[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propanoic acid; BAY-u3405



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Pugazhenthan Thangaraju, Gopinathan Narasimhan, Vijayakumar Arumugam Ramamurthy, Meenalochini Prakash Gurunthalingam, Sree Sudha Tanguturi Yella, Sajitha Venkatesan, Eswaran Thangaraju. Molecular Docking Analysis of Adhatoda vasica with Thromboxane A2 Receptor (TXA2R) (6IIU) and Antiviral Molecules for Possible Dengue Complications. Infectious disorders drug targets. 2023; 23(1):e180722206836. doi: 10.2174/1871526522666220718101544. [PMID: 35850647]
  • Kate C Chiang, John G Rizk, Deanna J Nelson, Lakshmanan Krishnamurti, Selvakumar Subbian, John D Imig, Imran Khan, Srinivasa T Reddy, Ajay Gupta. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert opinion on therapeutic targets. 2022 01; 26(1):13-28. doi: 10.1080/14728222.2022.2031975. [PMID: 35068281]
  • Ajay Gupta, Kate Chander Chiang. Prostaglandin D2 as a mediator of lymphopenia and a therapeutic target in COVID-19 disease. Medical hypotheses. 2020 Oct; 143(?):110122. doi: 10.1016/j.mehy.2020.110122. [PMID: 32759007]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • Hong-qiang Lou, Yan-feng Ying, Ye Hu. [CRTH2 antagonist ameliorates airway inflammation in rats with asthma]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences. 2010 01; 39(1):64-70. doi: 10.3785/j.issn.1008-9292.2010.01.011. [PMID: 20175238]
  • Kosuke Akiyama, Masayuki Karaki, Ryuichi Kobayshi, Hiroaki Dobashi, Toshihiko Ishida, Nozomu Mori. IL-16 variability and modulation by antiallergic drugs in a murine experimental allergic rhinitis model. International archives of allergy and immunology. 2009; 149(4):315-22. doi: 10.1159/000205577. [PMID: 19295235]
  • Rie Nomiya, Mitsuhiro Okano, Tazuko Fujiwara, Megumi Maeda, Yoshinobu Kimura, Kosuke Kino, Minehiko Yokoyama, Hiroyuki Hirai, Kinya Nagata, Toshifumi Hara, Kazunori Nishizaki, Masataka Nakamura. CRTH2 plays an essential role in the pathophysiology of Cry j 1-induced pollinosis in mice. Journal of immunology (Baltimore, Md. : 1950). 2008 Apr; 180(8):5680-8. doi: 10.4049/jimmunol.180.8.5680. [PMID: 18390753]
  • Petra Schratl, Eva M Sturm, Julia F Royer, Gunter J Sturm, Irmgard T Lippe, Bernhard A Peskar, Akos Heinemann. Hierarchy of eosinophil chemoattractants: role of p38 mitogen-activated protein kinase. European journal of immunology. 2006 Sep; 36(9):2401-9. doi: 10.1002/eji.200535672. [PMID: 16906532]
  • Aaron N Hata, Terry P Lybrand, Lawrence J Marnett, Richard M Breyer. Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2. Molecular pharmacology. 2005 Mar; 67(3):640-7. doi: 10.1124/mol.104.007971. [PMID: 15563582]
  • Hiroko Kariyazono, Kazuo Nakamura, Junko Arima, Osamu Ayukawa, Shunji Onimaru, Hiroshi Masuda, Yoshifumi Iguro, Hideyuki J Majima, Ryuzo Sakata, Katsushi Yamada. Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2004 Mar; 15(2):157-67. doi: 10.1097/00001721-200403000-00007. [PMID: 15091003]
  • Toshiaki Ishizuka, Takemi Matsui, Akira Kurita. Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. European journal of pharmacology. 2003 May; 468(1):27-35. doi: 10.1016/s0014-2999(03)01626-1. [PMID: 12729840]
  • S Holt, R Marley, B Fernando, D Harry, R Anand, D Goodier, K Moore. Acute cholestasis-induced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney international. 1999 Jan; 55(1):271-7. doi: 10.1046/j.1523-1755.1999.00252.x. [PMID: 9893136]
  • W Steinke, H J Ahr, M Hirayama. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 2nd communication: distribution to organs and tissues in male, female and pregnant rats, and characteristics of protein binding in plasma. Arzneimittel-Forschung. 1997 Aug; 47(8):939-48. doi: NULL. [PMID: 9296280]
  • M Boberg, H J Ahr, B Beckermann, K Bühner, H M Siefert, W Steinke, C Wünsche, M Hirayama. Pharmacokinetics and metabolism of the new thromboxane A2 receptor antagonist ramatroban in animals. 1st communication: absorption, concentrations in plasma, metabolism, and excretion after single administration to rats and dogs. Arzneimittel-Forschung. 1997 Aug; 47(8):928-38. doi: NULL. [PMID: 9296279]
  • A Okazawa, I Kawikova, Z H Cui, B E Skoogh, J Lötvall. 8-Epi-PGF2alpha induces airflow obstruction and airway plasma exudation in vivo. American journal of respiratory and critical care medicine. 1997 Feb; 155(2):436-41. doi: 10.1164/ajrccm.155.2.9032175. [PMID: 9032175]
  • K Rajakulasingam, S L Johnston, J Ducey, W Ritter, P H Howarth, S T Holgate. Effect of thromboxane A2-receptor antagonist on bradykinin-induced bronchoconstriction in asthma. Journal of applied physiology (Bethesda, Md. : 1985). 1996 Jun; 80(6):1973-7. doi: 10.1152/jappl.1996.80.6.1973. [PMID: 8806903]
  • S L Johnston, N J Freezer, W Ritter, S O'Toole, P H Howarth. Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. The European respiratory journal. 1995 Mar; 8(3):411-5. doi: 10.1183/09031936.95.08030411. [PMID: 7789486]
  • P Canale, F Squadrito, D Altavilla, M Ioculano, G M Campo, G Squadrito, G Urna, A Sardella, A P Caputi. Beneficial effects of BAY u3405, a novel thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock. Pharmacology. 1994 Dec; 49(6):376-85. doi: 10.1159/000139256. [PMID: 7878075]
  • S Bellucci, W Kedra, H Groussin, N Jaillet, P Molho-Sabatier, B Andreassian, G Tobelem. Ex vivo inhibition of platelet aggregation in patients with severe limb arteriopathy treated with BAY U3405, a specific TX A2 receptor antagonist. Thrombosis and haemostasis. 1994 Nov; 72(5):659-62. doi: 10.1055/s-0038-1648937. [PMID: 7900069]
  • D Altavilla, P Canale, F Squadrito, A Sardella, L Ammendolia, G Urna, M Ioculano, G Squadrito, A P Caputi. Protective effects of BAY U 3405, a thromboxane A2 receptor antagonist, in endotoxin shock. Pharmacological research. 1994 Aug; 30(2):137-51. doi: 10.1016/1043-6618(94)80005-7. [PMID: 7816742]
  • H F Kotzé, S Lamprecht, P N Badenhorst, V van Wyk, J P Roodt, K Alexander. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist. Thrombosis and haemostasis. 1993 Oct; 70(4):672-5. doi: NULL. [PMID: 8115994]
  • F Squadrito, M Ioculano, D Altavilla, B Zingarelli, P Canale, G M Campo, A Saitta, S Oriti, A Faggiotto, A P Caputi. Reduction of myocardial leukocyte accumulation and myocardial infarct size following administration of BAY u3405, a thromboxane A2 receptor antagonist, in myocardial ischaemia-reperfusion injury. Agents and actions. 1993 Jul; 39(3-4):143-9. doi: 10.1007/bf01998967. [PMID: 8304242]
  • S L Johnston, P G Bardin, J Harrison, W Ritter, J R Joubert, S T Holgate. The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations. British journal of clinical pharmacology. 1992 Nov; 34(5):402-8. doi: 10.1111/j.1365-2125.1992.tb05649.x. [PMID: 1467134]
  • F Seuter, E Perzborn, V B Fiedler, U Rosentreter, H Böshagen. Effect of BAY U 3405, a new thromboxane antagonist, on sudden death in rabbits. Journal of lipid mediators. 1991 May; 3(3):283-8. doi: ". [PMID: 1773029]
  • X L Ma, A Karasawa, A M Lefer. Mechanism of the protective action of Bay-u-3405, a new specific thromboxane receptor antagonist, in arachidonate-induced sudden death. Methods and findings in experimental and clinical pharmacology. 1991 Mar; 13(2):105-10. doi: NULL. [PMID: 1906568]
  • E Perzborn, V B Fiedler, F Seuter, J P Stasch, H Weber, E Sander, H Böshagen, U Rosentreter. Characterization of Bay U 3405, a novel thromboxane A2/endoperoxide receptor antagonist. Stroke. 1990 Dec; 21(12 Suppl):IV143-5. doi: NULL. [PMID: 2148034]
  • F Seuter, E Perzborn, U Rosentreter, H Böshagen, V B Fiedler. Inhibition of platelet aggregation in vitro and ex vivo by the new thromboxane antagonist (3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid. Arzneimittel-Forschung. 1989 Dec; 39(12):1525-7. doi: NULL. [PMID: 2624599]